Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/ Immunomodulators plus dexamethasone/ prednisone for the treatment of multiple myeloma: An indirect-comparison Metaanalysis of randomised controlled